LB.3 Clinically-Ascertained and Undiagnosed Hepatitis C Incidence Among Non-Injecting HIV-Positive Men-Who-Have-Sex-with-Men

Wednesday, March 14, 2012: 4:20 PM
Regency
Phillip Coffin, MD, MIA1, Matthew Golden, MD, MPH2, Robert Harrington, MD3, John Scott, MD, MSc3 and Paul Swenson, PhD4, 1HIV Prevention Section, San Francisco Department of Public Health, San Francisco, CA, 2Center for AIDS and STD, University of Washington, Seattle, WA, 3Division of Infectious Diseases, University of Washington, Seattle, WA, 4Prevention Division, Seattle/King County Department of Health, Seattle, WA

Background: Recent studies demonstrate elevated risk of hepatitis C (HCV) acquisition among HIV+ men-who-have-sex-with-men (MSM).

Objectives: Determine HCV incidence among HIV+ MSM through chart review and testing stored specimens.

Methods: We obtained de-identified data from all MSM participating in the University of Washington HIV Repository.  We tested the most recent stored specimen from men without a HCV diagnosis for HCV antibody and RNA. For RNA-positive subjects, the earliest available specimen was tested.

Results: Of 477 MSM without evidence of drug injection, mean age at most recent HCV test was 49 years; 72% were white, 14% African-American, 6% black African, and 4% Asian. Clinicians tested 96% for HCV at least once; 28 (5.9%) had evidence of HCV and 21 (4.4%) had chronic hepatitis C (CHC). Among 448 men with initial negative HCV tests, clinicians retested 222 (49.6%) in routine clinical care; repeated testing was associated with elevated alanine aminotransferase (OR 2.8;95%CI:1.7-4.7) and identified 23 cases of incident HCV. The study identified 7 additional HCV cases through stored specimens; 6 were confirmed incident. Overall HCV and CHC incidence was 10.4 (95%CI: 7.2-=15.0) and 9.7 (95%CI: 6.6-14.1) per 1000 person years, respectively. Incidence of clinically-undetected HCV and CHC was 2.2 (1.0-5.0) and 1.9 (95%CI: 0.7-4.5) per 1000 person years, respectively. On multivariate analysis, HCV incidence was associated with age (HR 0.7;95%CI:0.6-0.8), abuse of cocaine or opiates (HR 3.8;95%CI:1.7-8.8) and black African (HR 23.8;95%CI:9.0-62.8) or Asian (HR 5.2;95%CI:1.7-15.7) versus white race. There was no association with alanine aminotransferase, CD4 nadir, HIV viral load, amphetamine abuse, gonorrhea, chlamydial infection or syphilis.

Conclusions: Although HCV incidence among non-injecting HIV+ MSM in Seattle is relatively high and similar to that observed in Europe, most cases are detected without routine annual screening.

Implications for Programs, Policy, and Research: Results do not support routine annual HCV screening of HIV+MSM. Further research is required to elucidate factors associated with incident HCV.